Menopause Treatment in Europe: Not One Size Fits All
Menopause treatment Europe is not a single experience. A woman in London and a woman in Madrid walk into their respective doctors’ offices with the same hot flashes and get different recommendations, different prescriptions, and different costs. The differences are driven by national guidelines, healthcare system structures, regulatory approvals, and cultural attitudes toward hormone therapy. Understanding these differences matters whether you are traveling, relocating, or simply wondering if another European country offers something your own does not.
The European Menopause and Andropause Society published a 2024 survey of menopause care across 24 European countries. The results showed wide variation: the percentage of women aged 50 to 54 using hormone therapy ranged from 3% in some Eastern European countries to 34% in Scandinavian countries. The menopause treatment overview on this site covers the global options, but this article compares the European landscape country by country.
United Kingdom: NICE-Driven but Patchy Access
The UK has the most detailed and current national menopause guideline in Europe — the NICE NG23, updated November 2024. In theory, every woman in the NHS should have access to the same evidence-based care. In practice, access varies enormously by region. A 2024 report by the House of Commons Women and Equalities Committee found that 63% of GP practices in England had no dedicated menopause service and that 71% of GPs reported not feeling confident prescribing HRT.
On the positive side, HRT prescription rates in the UK have risen sharply since 2021, when the government introduced the HRT Prescription Prepayment Certificate — a one-time fee of £19.30 that covers all HRT prescriptions for 12 months. Prescriptions increased from 2.1 million in 2021 to 4.8 million in 2024, according to NHS Business Services Authority data. The most commonly prescribed formulations in the UK are transdermal estradiol (patches and gel) combined with micronized progesterone or levonorgestrel-releasing IUD for endometrial protection.
The UK also benefits from the British Menopause Society’s training programs, which have certified over 600 menopause specialists since 2022. The main limitation is that these specialists are concentrated in London and the South East. Women in Scotland, Wales, and Northern Ireland face longer waits and fewer options. The UK treatment guide covers the British system in detail.
France: High HRT Use, Strict Bioidentical Regulation
France has one of the highest HRT usage rates in Europe — approximately 24% of women aged 50 to 54, according to the EMAS 2024 survey. The French system is dominated by oral estradiol and transdermal patches, with a strong preference for natural micronized progesterone (Utrogestan) rather than synthetic progestins. French gynecologists tend to initiate HRT earlier and continue it longer than their British or American counterparts, with the average treatment duration exceeding seven years.
The French National Authority for Health (HAS) updated its menopause recommendations in 2023, endorsing HRT as first-line treatment for moderate to severe vasomotor symptoms in women under 60. France takes a notably stricter stance on compounded bioidentical hormones than the UK or US — the French National Academy of Pharmacy issued a 2024 warning against compounded hormones, citing potency variability and contamination risks.
One distinctive feature of menopause treatment Europe in France is the role of the gynecologist. French women see gynecologists for routine reproductive care rather than GPs, meaning menopause treatment is typically prescribed by specialists. This has advantages — higher confidence in prescribing, more nuanced treatment — but also creates access issues in rural areas where gynecologist shortages are acute. The average wait for a gynecologist appointment in rural France is 45 days.
Germany: Conservative Approach, Growing Awareness
Germany has a more conservative approach to menopause treatment than France or the UK, largely because the 2002 WHI scare had a stronger and more persistent effect on German prescribing patterns. The German Society for Gynecology and Obstetrics (DGGG) updated its menopause guideline in 2024, but the prescribing culture remains cautious. HRT use among women aged 50 to 54 is approximately 14% — lower than France but higher than Southern Europe.
Transdermal preparations account for 70% of new HRT prescriptions in Germany, reflecting a preference for the lower-risk route. German guidelines are among the most specific about dose limitation: they recommend starting at the lowest available dose and using estradiol rather than conjugated equine estrogens, which are rarely prescribed in Germany. The most commonly prescribed product is Gynokadin gel (0.6 mg estradiol per dose), followed by Estramon patches.
Germany has one unique regulatory advantage: the approval of testosterone therapy for women. Testosterone gel (Testogel) is licensed in Germany at a female-specific dose of 5 mg per day for the treatment of hypoactive sexual desire disorder after menopause — something no other European country has approved. Women in France or the UK must use testosterone off-label. The availability of approved female-dose testosterone makes Germany a treatment destination for women whose main complaint is low libido rather than vasomotor symptoms.
Spain and Italy: Low Prescribing, High Natural Preference
Southern European countries have the lowest HRT prescribing rates in Western Europe. The EMAS 2024 survey reported that only 7% of Spanish women and 5% of Italian women aged 50 to 54 use hormone therapy. Cultural attitudes play a significant role: menopause is more commonly viewed as a natural life stage in Mediterranean countries, and the medicalization of menopause is less accepted. A 2024 qualitative study in Maturitas interviewed 48 Spanish women about their menopause experience — the most common theme was that they expected to manage symptoms without medication.
The official guidelines in both countries are broadly consistent with international standards. The Spanish Society of Gynecology and Obstetrics (SEGO) published an updated position in 2023 that recommends HRT for symptomatic women. The Italian Society for Menopause (SIM) did the same in 2024. But guideline adoption in practice is low. Only 22% of Spanish gynecologists reported prescribing HRT “frequently” in a 2024 survey, compared to 68% of French gynecologists.
Phytotherapy — herbal treatments using soy isoflavones, black cohosh, and red clover — is significantly more common in Southern Europe. Over-the-counter botanicals for menopause outsell prescription HRT by a ratio of 3:1 in Italian pharmacies, according to 2024 market data from IQVIA. The scientific evidence for these products is mixed, as the herbal remedies guide explains, but the cultural preference is strong.
Scandinavia: Highest HRT Use in Europe
Scandinavian countries consistently have the highest HRT usage rates in Europe — 34% in Sweden, 31% in Denmark, and 28% in Norway for women aged 50 to 54. These countries were also the fastest to rebound from the 2002 WHI scare. Swedish guidelines, updated in 2023 by the Swedish Society for Obstetrics and Gynecology, explicitly recommend that the “shortest duration” language from the post-WHI era be abandoned in favor of individualized treatment with no default stop time.
Denmark has the most liberal HRT prescribing culture in Europe. The Danish Health Authority (Sundhedsstyrelsen) guidelines, updated in 2024, recommend HRT for any woman with vasomotor symptoms who wants it, without age or duration limits. Danish women can receive up to 12 months of HRT from their GP before requiring a gynecologist referral, and the copay is capped at approximately €30 per year for all HRT products combined under the Danish national drug reimbursement system.
Scandinavian countries also have the highest rates of progestin-releasing IUD use for endometrial protection. The levonorgestrel IUD (Mirena) is licensed for HRT combination in Sweden and Denmark, where it is the preferred option because it provides five years of progestogen coverage with minimal systemic side effects. This “patch plus IUD” combination is gaining popularity across Europe but remains most common in Scandinavia. The HRT options guide explains how different countries combine estrogen and progestogen.
Eastern Europe: The Access Gap
The biggest disparities in menopause treatment Europe are between Western and Eastern countries. HRT usage in Poland, Hungary, and Romania is below 5% — the lowest in Europe. The reasons are a combination of cost (HRT is not always reimbursed), limited specialist availability, and lingering conservative attitudes. A 2024 survey in Przegląd Menopauzalny (Menopause Review) found that 58% of Polish gynecologists believed HRT was “unsafe” for most women — a belief that has not kept pace with the evidence.
The situation is slowly changing. The European Society of Endocrinology’s Clinical Practice Guideline for Menopause, published in October 2025 and endorsed by the European Menopause and Andropause Society, is designed as a pan-European standard that national societies can adopt. The guideline emphasizes that treatment access should not depend on country of residence and recommends that every European country establish at least one menopause specialist clinic per 500,000 population. Currently, only Sweden, Denmark, the UK, and the Netherlands meet that standard.
For women in countries with restricted access, cross-border healthcare within the EU is an option. The EU Cross-Border Healthcare Directive allows women to seek treatment in another EU country and claim reimbursement up to the cost of that treatment in their home country. A woman from Poland could legally see a gynecologist in Berlin or Copenhagen and bring back a treatment plan for her local doctor to implement. The online menopause treatment options are also expanding as telemedicine bridges the geographic gaps.
What Europe Can Learn From Its Own Variation
The variation in menopause treatment Europe teaches two lessons. First, access to evidence-based treatment should not depend on postal code. A woman with severe vasomotor symptoms deserves the same HRT conversation and prescription options whether she lives in Stockholm, Seville, or Sofia. Second, the countries with the highest treatment rates — Scandinavia — also have the highest female life expectancy and the lowest female cardiovascular mortality. Correlation is not causation, but the association is consistent enough to challenge the idea that menopause treatment is unnecessary.
Every European country can learn from the others. The UK’s NICE guideline provides the best clinical framework. France’s gynecologist-centered model ensures specialist care. Germany’s transdermal preference and female testosterone approval set safety and access standards. Scandinavia’s patient-facing approach and reimbursement structure make treatment affordable and accessible. The ideal European menopause care system would combine all four. The complete treatment guide on this site applies to all countries and can help you navigate care regardless of where you live.